CureVac N.V. (CVAC)
NASDAQ: CVAC · IEX Real-Time Price · USD
2.665
+0.015 (0.57%)
Apr 16, 2024, 4:30 PM EDT - Market closed

Company Description

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).

It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.

The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck.

CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

CureVac N.V.
CureVac logo
Country Germany
Founded 2000
IPO Date Aug 14, 2020
Industry Biotechnology
Sector Healthcare
Employees 904
CEO Dr. Alexander Zehnder M.B.A., M.D.

Contact Details

Address:
Paul-ehrlich-strabe 15 Tubingen
Baden-wurttemberg, 2M 72076
Germany
Phone 49 7071 9883 0
Website curevac.com

Stock Details

Ticker Symbol CVAC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001809122
CUSIP Number N2451R105
ISIN Number NL0015436031
SIC Code 2834

Key Executives

Name Position
Pierre Kemula B.Sc. MD, Chief Financial Officer and Member of Management Board
Dr. Malte Greune Ph.D. Chief Operating Officer, Member of Management Board and MD
Dr. Ulrike Gnad-Vogt M.D., Ph.D. Senior Vice President and Area Head of Oncology
Dr. Alexander Zehnder M.B.A., M.D. Chief Executive Officer, MD and Member of Management Board
Dr. Myriam Mendila M.D. Chief Development Officer, MD and Member of the Management Board
Dr. Sarah Fakih Vice President Corporate Communications and Investor Relations
Marco Rau L.L.M., Ph.D. General Counsel
Thorsten Schuller Head of Corporate Communications
Slavica Stevanovic-Heck Head of Human Resources
Dr. Patrick Baumhof Senior Vice President of Technology

Latest SEC Filings

Date Type Title
Apr 16, 2024 6-K Report of foreign issuer
Apr 12, 2024 144 Filing
Apr 4, 2024 6-K Report of foreign issuer
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 6, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 17, 2024 6-K Report of foreign issuer
Jan 5, 2024 6-K Report of foreign issuer
Jan 5, 2024 144 Filing
Jan 5, 2024 144 Filing
Jan 5, 2024 144 Filing